SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 27, 2003; DOI 10.1182/blood-2003-01-0014. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-01-0014v1 102/3/810    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nieva, J. Articles by Saven, A. Search for Related Content PubMed PubMed Citation Articles by Nieva, J. Articles by Saven, A. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 August 2003, Vol. 102, No. 3, pp. 810-813 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia Jorge Nieva, Kelly Bethel, and Alan Saven From the Division of Hematology/Oncology and Department of Pathology, Scripps Clinic, La Jolla, CA; and the Scripps Cancer Center, La Jolla, CA Hairy cell leukemia (HCL) is an indolent B-cell neoplasm, strongly expressing CD20. Despite initial very high response rates following cladribine, many patients (pts) ultimately relapse. Having relapsed after prior treatment with cladribine, 24 HCL pts (21 male, 3 female) with a median age of 53.5 years were treated with rituximab at 375 mg/m2 intravenously weekly for 4 weeks. Of the pts, 3 (13%) achieved complete remissions and 3 (13%), partial responses. Thus, 6 (25%) of 24 pts achieved a response following rituximab. At a median follow-up of 14.6 months, 2 responders have relapsed; median time to relapse was not yet reached. The only grade III or IV toxicities demonstrated were culture-negative febrile neutropenia, transient and reversible disseminated intravascular coagulation related to rituximab administration, and a diverticular abscess, each in single patients. Of 18 nonresponders, 9 pts subsequently received other treatments; 5 pts were retreated with cladribine, 3 underwent splenectomy, and 1 received pentostatin. Follow-up data are available on 7 of these 9 patients; all 7 patients achieved improvements in hematologic parameters. Rituximab, administered at this dose and schedule, has only modest single-agent activity in cladribine-failed HCL patients when compared with other agents active in this disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. M. Golomb Hairy Cell Leukemia: Treatment Successes in the Past 25 Years J. Clin. Oncol., June 1, 2008; 26(16): 2607 - 2609. [Full Text] [PDF] F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al. Eradication of minimal residual disease in hairy cell leukemia Blood, June 15, 2006; 107(12): 4658 - 4662. [Abstract] [Full Text] [PDF] E. Arons, I. Margulies, L. Sorbara, M. Raffeld, M. Stetler-Stevenson, I. Pastan, and R. J. Kreitman Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin. Cancer Res., May 1, 2006; 12(9): 2804 - 2811. [Abstract] [Full Text] [PDF] R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies J. Clin. Oncol., September 20, 2005; 23(27): 6719 - 6729. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020